ReAlta Life Sciences目前正在全球范围内招募一项针对类固醇不敏感型aGVHD患者的2期临床试验，展示出RLS-0071在未来治疗领域的巨大潜力。可以想象，未来可能有一天，我们甚至可以看到RLS-0071作为aGVHD患者的“守护神”！“这些结果强调了pegtarazimod独特的双重机制，能够同时在炎症级联反应中最早和最具破坏性的点上发挥作用。
Kenji Cunnion, MD, MPH, ReAlta Life Sciences Inc (Board Member, Employee, Shareholder) Parvathi Kumar, MBBS, ReAlta Life Sciences Inc (Employee) Brittany Lassiter, BS, ReAlta Life Sciences Inc (Employee) Katherine LaValle, DVM, ReAlta Life Sciences Inc (Employee) Neel Krishna, PhD, ReAlta ...
Department of Research and Medical Affairs NorfolkReAlta Life Sciences Norfolk Virginia USAPamela HairDepartment of Research and Medical Affairs NorfolkReAlta Life Sciences Norfolk Virginia USAParvathi KumarDepartment of Research and Medical Affairs NorfolkReAlta Life Sciences Norfolk Virginia USAGiuseppina ...